TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Environmental Analytics
Environmental and financial analysis dashboard for TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED. Industry: MANUFACTURING
Company Overview for TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
Highlights
Showing data for FY2022
Operational Environmental Cost
$16m
Operational Environmental Cost Intensity
1.38%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
$7.88m
Decoupling Rate (2020-2022)
-28%
Adjusted EBITDA
$143m
Adjusted EBITDA Margin
12%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| 16.50% | 57.59% | N/A | ||
| 0.29% | 0.31% | 0.45% | N/A | |
| 30.92% | 50.23% | N/A | ||
| 0.55% | 0.68% | 0.93% | N/A | |
| $9m | $11m | $16m | N/A | |
| 25.98% | 52.56% | N/A | ||
| 0.84% | 0.99% | 1.38% | N/A | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
12%
Adjusted EBIT Margin
11%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$1,014m | $1,084m | $1,187m | $1,159m | |
| 6.88% | 9.49% | -2.30% | ||
$879m | $928m | $1,027m | $981m | |
| 86.69% | 85.65% | 86.58% | 84.66% | |
$135m | $156m | $159m | $178m | |
| 13.31% | 14.35% | 13.42% | 15.34% | |
$118m | $137m | $142m | $160m | |
| 11.63% | 12.68% | 12.01% | 13.76% | |
| ENVIRONMENTAL COST DATA | ||||
$9m | $11m | $16m | N/A | |
| 0.84% | 0.99% | 1.38% | 0.00% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$126m | $145m | $143m | N/A | |
| 12.47% | 13.36% | 12.04% | 0.00% | |
$109m | $127m | $126m | N/A | |
| 10.79% | 11.68% | 10.62% | 0.00% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.45%
Scope 2 (% of Sales)
0.93%
Operational Environmental Cost Intensity
1.38%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED | N/A | $16m | 1.38% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | $44m | 47.50% | N/A | N/A |
Energy-related activities (3) | $24m | 26.13% | N/A | N/A |
Upstream transportation (4) | $6m | 6.50% | N/A | N/A |
Waste (5) | $1m | 0.76% | N/A | N/A |
Business travel (6) | $0m | 0.47% | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | $5m | 5.59% | N/A | N/A |
Processing of products (10) | $0m | 0.02% | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | $12m | 13.04% | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $92m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022